Inhibition of nuclear factor-kappaB attenuates atherosclerosis in apoE-LDLR - double knockout mice

• Autorzy: Jawien J. , Gajda M. , Mateuszuk L. , Olszanecki R. , Jakubowski A. , Szlachcic A. , Karabiowska M. , Korbut R.
• Języki publikacji: EN

Abstrakty

EN

Nuclear factor - B (NF-B) is a good therapeutic target for cardiovascular disease and numerous efforts are being made to develop safe NF-B inhibitors. Nowadays many authors address NF-B as a major therapeutic target in atherosclerosis, especially for preventive measures, in the light of two main hypothesis of atherosclerosis: oxidation and inflammation. We hypothesized that ammonium pyrrolidinedithioocarbamate (PDTC) - a well-known inhibitor of NF-B could inhibit the development of atherosclerosis in this experimental model. We used apoE/LDLR - DKO mouse model, which is considered as a one of the best models to study the anti-atherosclerotic effect of drugs. In this model PDTC inhibited atherogenesis, measured both by "en face" method (25,15±2,9% vs. 15,63±0,6%) and "cross-section" method (565867±39764 µm2 vs. 291695±30384 µm2). Moreover, PDTC did not change the profile of cholesterol and triglycerides in blood. To our knowledge, this is the first report that shows the effect of PDTC on atherogenesis in gene-targeted apoE/LDLR - double knockout mice.

Słowa kluczowe

EN

oxidation; mouse; knockout mice; mice; cardiovascular disease; inflammation; therapeutic target; atherosclerosis; nuclear factor-kappaB; apolipoprotein E

• Wydawca: -
• Czasopismo: Journal of Physiology and Pharmacology
• Rocznik: 2005
• Tom: 56
• Numer: 3
• Opis fizyczny: p.483-489,fig.,ref.

Twórcy

autor

Jawien J.

• Jagiellonian University Shool of Medicine, Grzegorzecka Str.16, 31-531 Krakow, Poland

autor

Gajda M.

autor

Mateuszuk L.

autor

Olszanecki R.

autor

Jakubowski A.

autor

Szlachcic A.

autor

Karabiowska M.

autor

Korbut R.